A crystalline form of 2-(3-(2,,5'-difluoro-[1,1'-biphenyl]-4-yl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonamide

EP4770752A1Pending Publication Date: 2026-07-08ASSEMBLY BIOSCIENCES INC
0 Cites 0 Cited by

Patent Information

Application Number
EP2024773576
Authority / Receiving Office
EP · EP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-08-28
Filing Date
2024-08-27
Publication Date
2026-07-08

AI Technical Summary

Technical Problem

Current treatments for herpes simplex virus (HSV) infections, such as nucleoside analogues, are inadequate in preventing recurrent outbreaks and addressing viral shedding, and they pose safety concerns due to mutagenicity.

Method used

A novel crystalline form of the potent helicase-primase inhibitor, 2-(3-(2',5'-difluoro-[1,1'-biphenyl]-4-yl)-2-oxotetrahydropyrimidin-1(2H)-yl)-4-methylthiazole-5-sulfonamide, referred to as Compound T or Form A, which is characterized by specific XRPD peaks and a high melting point, is developed for improved therapeutic efficacy.

Benefits of technology

The crystalline form of Compound 1, Form A, demonstrates enhanced stability and bioavailability, potentially leading to more effective suppression of HSV replication, reduced frequency and severity of outbreaks, and improved safety profile compared to existing treatments.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to a novel crystalline form of a helicase-primase inhibitor compound, as well as to pharmaceutical compositions comprising the same, methods for its production, the use of the crystalline form in a medicament and for the treatment of herpes virus infections.
Need to check novelty before this filing date? Find Prior Art